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RENATE: A Pseudo-retrosynthetic Tool for Synthetically
Accessible de Novo Design
Gian Marco Ghiandoni,[a] Michael J. Bodkin,[b] Beining Chen,[c] Dimitar Hristozov,[b] James E. A. Wallace,[b]
James Webster,[a] and Valerie J. Gillet*[a]
Abstract: Reaction-based de novo design refers to the
generation of synthetically accessible molecules using
transformation rules extracted from known reactions in the
literature. In this context, we have previously described the
extraction of reaction vectors from a reactions database
and their coupling with a structure generation algorithm for
the generation of novel molecules from a starting material.
An issue when designing molecules from a starting material
is the combinatorial explosion of possible product mole-
cules that can be generated, especially for multistep
syntheses. Here, we present the development of RENATE, a
reaction-based de novo design tool, which is based on a
pseudo-retrosynthetic fragmentation of a reference ligand
and an inside-out approach to de novo design. The
reference ligand is fragmented; each fragment is used to
search for similar fragments as building blocks; the building
blocks are combined into products using reaction vectors;
and a synthetic route is suggested for each product
molecule. The RENATE methodology is presented followed
by a retrospective validation to recreate a set of approved
drugs. Results show that RENATE can generate very similar
or even identical structures to the corresponding input
drugs, hence validating the fragmentation, search, and
design heuristics implemented in the tool.
Keywords: de novo drug design · reaction informatics · patents · pharmaceuticals
1 Introduction
In-silico de novo drug design consists of creating novel
molecules with desired properties.[1] These properties in-
clude biological activity, physicochemical properties, phar-
macokinetics, toxicity, and synthetic accessibility. Although
first introduced more than 30 years ago,[2] de novo design
remains a very challenging task due to the complex
relationships amongst these properties and the astronom-
ical number of valid structures that could be generated. A
major limitation of early de novo design was the inability to
account for the synthetic accessibility of products, which
resulted in its poor application to real problems.[3] Reaction-
based methods were introduced with the aim of accounting
for this limitation. These used small numbers of hard-coded
transformation rules (e.g. organic chemistry reactions)[4,5] to
address synthetic accessibility explicitly. More recently AI-
based methods have gained considerable popularity for de
novo design.[6,7] The initial focus was on the adoption of
techniques developed in natural language processing to
generate molecules as SMILES representations, with meth-
ods then extended to graph representations. However,
there is no explicit handling of synthetic accessibility in
these approaches.[8] Attention has now turned towards
combining reaction-based methods with machine learning
techniques for molecular generation. For example, machine
learning has been used to select building blocks to combine
using reaction rules[9] and to select preferred reactions to
apply to a given starting material.[10] Reaction-based
methods are now also being integrated with deep
reinforcement learning methods[11,12] where the reinforce-
ment learning is used to select which reaction template to
apply next. A more complex deep learning approach has
recently been proposed based on synthesis directed acyclic
graphs (synthesis DAGs) which encodes synthetic routes as
reaction schemes representations.[13]
The availability of large collections of publicly available
reactions has enabled reaction-based de novo design to be
extended beyond a small set of hand coded reaction rules.
We have adapted reaction vectors for this purpose.[14] The
reaction vector encodes the structural changes that take
place during a reaction into a vector with negative and
positive counts of atom pair descriptors indicating frag-
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ments that are removed from the reactants and introduced
into the products, respectively. Reaction vectors can be
calculated by simply subtracting the vector that represents
the reactants from that representing the products. We have
coupled the reaction vector with a structure generation
procedure which allows a reaction vector to be applied to a
new starting material and, provided that the starting
material contains the fragments to be removed (that is,
atom pairs corresponding to the negative atom pairs of the
reaction vector), a new product can be generated. The
reaction vectors are comprised of atom pair 2 and atom
pair 3 descriptors with atom pair 2 descriptors encoding the
bond changes in a reaction and atom pair 3 descriptors
extending the environment of the reaction that is encoded
in a sphere-based manner.
We have shown that reaction vectors can encode
chemistry correctly by applying them to their original
reactants to reproduce their corresponding products.[15] We
have also demonstrated the use of reaction vectors for
data-driven reaction classification by developing a model
called SHREC with a set of reactions extracted from the US
patent literature.[16] In a recent publication, we build a
reaction class recommender to enhance the synthetic
accessibility of reaction vector products by predicting which
reactions to apply to an input molecule according to its
fingerprint.[10] In the same publication, we briefly described
the validation of the recommender using an automated de
novo drug design tool called RENATE (REtrosynthetic desigN
using reAcTion vEctors).
An issue when designing molecules from a small
starting material is the huge combinatorial explosion of
possible product molecules that can be generated espe-
cially when multistep syntheses are considered. RENATE
aims to circumvent the combinatorial explosion by taking
an inside-out approach to de novo design. It is based on
the principles of pseudo-retrosynthetic de novo design
which was first proposed over 10 years ago.[17,18] For
example, in the Flux program a molecule is fragmented
using a small set of retrosynthetic rules. The same rules are
used to fragment molecules in a database which then form
building blocks for de novo design. The fragments of the
target molecule are used to identify similar building blocks
which are then recombined to generate novel molecules.
The term pseudo refers to the simplistic retrosynthetic
approach that breaks the bonds in a molecule without
accounting for functional conversions, eliminations, or ring
transformations. In Flux, the rules are the 11 bond-cleavage
types implemented in RECAP[19] and the building blocks are
connected via attachment points determined using RECAP.
The key advance in RENATE is in the construction phase
where the retrieved fragments are combined using reaction
vectors. The product molecules are therefore based on
reactions for which precedents exist in the literature and
synthetic accessibility is accounted for explicitly by the use
of real reagents and reactions during the structure gen-
eration step.
Here we describe the implementation of RENATE in
detail and its retrospective validation on a large set of
approved drugs. We show that RENATE can be controlled
by user-defined sources of reagents and reactions, scoring
functions and parameters. We compare the use of two
reaction vector sources from the US patent literature and
the Journal of Medicinal Chemistry, respectively, and
determine an optimal setup for de novo design. The results
from the validation demonstrate that RENATE can generate
relevant drug candidates and provide references for their
synthesis. The use of RENATE in a real case study will be
described in a future publication.
2 Methods
2.1 The RENATE Algorithm
RENATE is a pseudo-retrosynthetic de novo design tool that
fragments a molecule, searches for sets of similar fragments
and then combines these using the reaction-based struc-
ture generator to generate novel product molecules.
Synthetic accessibility is accounted for explicitly through
the use of reaction vectors which are derived from known
reactions and fragments which are extracted from a data-
base of available molecules. RENATE is composed of four
modules: ligand fragmentation, building block search, struc-
ture generation and scoring. An example of a pseudo-
retrosynthetic de novo design scheme is illustrated in
Figure 1.
The ligand fragmentation module breaks a reference
ligand or query into key fragments from which the
molecular scaffold is identified with the remaining frag-
ments identified as substituents. The fragmentation is done
using the BRICS[20] module in RDKit. BRICS can be consid-
ered an extension of the RECAP approach that consists of
16 bond-cleavage rules. Once key fragments are produced,
they are sorted first by descending number of connections
and then by number of heavy atoms. The fragment at the
top of the ranked list is identified as the scaffold and forms
the basis of the search for starting materials. This heuristic
ensures that the candidate molecules are constructed from
‘the inside out’. The fragmentation module is controlled by
two parameters: minFragmentSize and minKeyFragSize.
minFragmentSize determines which bonds can be broken in
BRICS according to the resulting fragment size, whereas,
minKeyFragSize is the sum of the number of heavy atoms
and the number of connections and is used to filter out
fragments that are too small to be considered relevant,
hence reducing the number of design iterations. An
example of the fragmentation procedure is shown in
Figure 2 for Celecoxib.
The building block search module takes the scaffold and
each substituent fragment in turn and performs a search on
an external source of structures (e.g. a reagent catalogue)
to retrieve similar reagents based on a user-defined
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similarity measure. In the examples shown here similarity is
calculated using 1024-bit binary Morgan fingerprints (radius
2) and the Tanimoto coefficient. For each fragment query,
the search returns a set of starting materials and sets of
reagents sorted on similarity to the parent fragment. For
example, given a scaffold ‘A’ and a substituent ‘B’, the
algorithm returns two sets of reagents (e.g. {a1, a2, …, ax},
{b1, b2, …, by}) scored by similarity. The sizes of the sets are
controlled by the parameters maxStartingMaterials and
maxReagents.
The structure generation module implements a logic
similar to that in synthetic chemistry. In the first design
cycle, the structure generator combines the fragments
retrieved for the scaffold (considered as starting materials)
with those retrieved for the first substituent (considered as
reagents) using the available set of reaction vectors. For
example, the sets {a1, a2, …, ax} and {b1, b2„ …, by} are
considered. For each pair of fragments (one from set a and
one from set b), the set of reaction vectors is searched and
for each applicable reaction vector, a product molecule is
generated. A reaction vector is applicable if its negative
atom pairs, which encode the parts of reactant(s) that are
transformed into product, are present within the combined
atom pairs of the starting material and reagent currently
being processed. Not all reaction vectors will be applicable
to all pairs of fragments. This step results in a set of product
molecules of the form (a1-b3, b2-a5, …, a9-b11,…}. The
products are scored (see below), and the top scoring
products form a new set of starting materials. These are
then input to the structure generator to be combined with
the reagents retrieved for the second substituent (e.g. {c1,
c2, …, cz}). The algorithm iterates until all substituents have
been considered. At the end of each iteration, the product
selection is controlled using two more parameters: query-
HeavyAtomsAddThreshold is used to filter out products
according to the size of the query ligand. For example, if
queryHeavyAtomsAddThreshold is equal to 0.25, then prod-
ucts exceeding 25% of the heavy atom count of the query
ligand are filtered out. numProductsCycle determines how
many products are retained at the end of each iteration for
the next round of structure generation.
The scoring module is defined by the user. In the
simplest implementation of RENATE, it is configured as a
similarity-based method that selects the best molecules
based upon their similarity to the query. The scoring module
first drives the design by selecting the best products at the
end of each cycle (active scoring), then finally sorts the
entire population of intermediates and final products to
yield a set of candidates (passive scoring). The total number
of candidates retained by the algorithm for a given query is
controlled by the parameter numFinalProducts. A GUI
version of RENATE was implemented using KNIME[21] as
described in Figure 3.
Figure 1. Pseudo-retrosynthetic de novo design applied to the molecule Celecoxib. The query ligand bonds are (a) broken to yield a set of
key fragments. Fragments are then used to retrieve similar structures that are (b) recombined to yield novel compounds that are similar to
the query ligand.
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3 Retrospective Validation
RENATE was validated by applying it to a set of approved
drugs to assess whether the algorithm could either recreate
the drugs or molecules that are similar to the drugs. The
experiment had two aims: first, to verify the assumptions
made by the algorithm (correct fragmentation and starting
material/reagent role assignment) and, second, to deter-
mine whether the selected reagent catalogue and reaction
vector databases would enable effective designs in drug-
like space.
A collection of drugs from the top 200 medicines
prescribed in the US in the year 2017 (https://clincalc.com/
DrugStats/) was used as a reference set for the validation.
The drugs were drawn using MarvinSketch and converted
into SMILES which were sanitised using RDKit,[22] then salts
and ions were stripped to obtain one molecule per entry.
Several filters were applied to obtain a subset of the drugs
to benchmark the performance of RENATE: a minimum of
20 atoms (heavy atoms and hydrogens), a maximum of
three fused rings, a minimum of two rings, a maximum of
one Lipinski’s violation.[23] Next, a diverse subset was
selected by calculating the pairwise similarities between all
molecules and retaining only one molecule for each pair
with a similarity greater than or equal to 0.6. Similarities
were calculated using 1024-bit binary Morgan fingerprints
(radius 2) and the Tanimoto coefficient. The filtering yielded
73 structures which are reported in the Supporting
Information.
A set of 746,272 reagents was obtained from the
Enamine website (sanitised using RDKit, neutralised, then
deduplicated using InChI Keys) and selected as a source of
starting materials and reagents. Any of the 73 reference
drugs that were present in the Enamine set were filtered
out to prevent the algorithm from picking the complete
drug structure during the design. Two different sources of
reaction vectors were used: 92,530 obtained from the US
Patent Database (referred to as USPD); and 7,109 obtained
from the Journal of Medicinal Chemistry (JMC 2018). The
USPD reaction vectors were obtained following the encod-
ing of the 115 K unique reactions as described in Ghiandoni
et al.[16] The JMC 2018 set consisted of 7,109 unique reaction
vectors obtained from 27 K reactions as described in
Ghiandoni et al.[10] 1024-count Morgan fingerprints (radius
2) and Euclidean distance were selected for the scoring of
both building blocks and products. The selection of
structural fingerprints as scoring function was aimed at
maximising the chance of reproducing the reference drugs.
The design workflows were carried out using the USPD
and JMC 2018 reaction vectors, respectively, in order to
determine the sensitivity of the approach to the source of
reaction vectors. The parameters used in the experiments
are reported in the Supporting Information.
4 Results
11 of the drugs (15%) failed the BRICS fragmentation step.
The decomposition mainly failed due to the lack of rules for
the fragmentation of single bonds between aromatic and
aliphatic rings. These failures indicate that BRICS lacks some
important fragmentation rules. Some examples of failed
queries are reported in Figure 4. The remaining 62 drugs
were successfully processed by both BRICS and RENATE.
The top scoring compound (closest reproduction) per
drug was retained and the pairwise similarity to the parent
drug was calculated using four binary fingerprints: 1024-bit
RDKit Morgan (radius 2) (equivalent of ECFP4) and CDK
ECFP4, 1024-bit RDKit FeatMorgan (radius 2) (equivalent of
FCFP4) and CDK FCFP4. The minimum, maximum, mean
Figure 2. Ligand fragmentation results for the molecule Celecoxib.
The pyrazole is identified as the starting material (molecular
scaffold) due to the higher number of connections compared to
the other fragments, which are, therefore, considered as reagents
(substituents).
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and median pairwise similarities for the 62 drugs are
reported in Table 1 for the USPD and JMC 2018 designs.
The USPD and JMC 2018 values in Table 1 show that the
USPD reaction vectors produced structures that were on
average more similar to the target drugs. This is not
surprising as the USPD database contains 13 times the
number of reaction vectors as the JMC 2018 database. Each
top-scoring compound from the USPD design was also
visually inspected and compared with the parent drug.
Some examples of the top candidates and their parent
drugs are reported in Figure 5, sorted on increasing
similarity. This shows that candidates with similarities great-
er than 0.5 are very similar to the parent drug. For example,
the top scoring candidate for Tizanidine (0.53 similarity)
presents minor variations on the five-membered ring, and
Cephalexin’s candidate (0.78 similarity) differs only in the
substitution of an amino group with a methyl. 70% and
47% of the top scoring candidates had similarity greater
than 0.5 to the parent for the USPD and JMC 2018
experiments, respectively. These results suggest that the
USPD reactions is a preferred source of reaction vectors for
Figure 3. RENATE KNIME workflow: Query molecules are fragmented and used to find fragments similar to the scaffold (which form starting
materials) and each of the substituents (to form lists of reagents). The fragments returned from the scaffold search are written to a
temporary file, which is read by the structure generator as a starting population. Once the starting materials have been combined with the
first set of reagents, the new population is scored and overwrites the temporary table. RENATE iterates through each reagent set while
reading and overwriting the temporary table until the process is complete. The final population is then rescored and written out.
Figure 4. Drugs that failed the BRICS decomposition. Potential fragmentation bonds are highlighted in bold.
Table 1. Statistics from the pairwise similarities between queries
and their closest reproductions from the USPD and JMC 2018
designs.
Design Binary Fingerprint Min Max Mean Median
USPD RDKit-ECFP4 0.19 1.00 0.62 0.60
CDK-ECFP4 0.18 1.00 0.62 0.61
RDKit-FCFP4 0.29 1.00 0.64 0.64
CDK-FCFP4 0.23 1.00 0.65 0.64
JMC 2018 RDKit-ECFP4 0.15 1.00 0.51 0.48
CDK-ECFP4 0.12 1.00 0.50 0.48
RDKit-FCFP4 0.16 1.00 0.51 0.45
CDK-FCFP4 0.21 1.00 0.52 0.52
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de novo design compared to the considerably smaller JMC
2018 set.
The USPD and JMC 2018 pipelines reproduced 6 and 1
of the drugs, respectively. More specifically, using the USPD
reaction vectors, three, two, and one of the drug were
regenerated via 1-step, 2-step, and 3-step synthetic routes,
respectively, while for the JMC 2018 reaction vectors the
one drug that was reproduced was using a 2-step synthetic
route. The virtual synthetic routes of the reproduced drugs
were also inspected and compared with the actual routes
used to produce the drugs using the original patents as
references. Table 2 compares the number of virtual and real
synthetic steps (using the original patents as references) per
reproduced drug. The comparison between virtual and the
real synthetic schemes in the patents revealed that none of
the drugs was reproduced using their original references.
This result can be rationalized as follows. First, some of the
reference patents were not issued in the US, hence their
reactions are not necessarily in the USPD set. Second,
patents often describe combinations of small and cheap
building blocks, whereas RENATE makes use of a vast
catalogue of reagents, which can also contain analogues of
the queries (e.g., the Naproxen and Levofloxacin designs
Figure 5. Examples of some closest reproduction-drug pairwise similarities using RDKit-ECFP4 generated from the USPD design.
Table 2. Virtual and real synthetic steps, plus original patent
references, for each reproduced drug from the USPD and JMC 2018
designs.
Design Drug Virtual Steps Real Steps (Patent Reference)
USPD Brimonidine 1 3 (US3890319 A)
Glipizide 2 2 (DE2012138)
Glyburide 2 3 (DE1283837)
Levofloxacin 1 7 (US4382892 A)
Naproxen 1 8 (US3896157)
Rivaroxaban 3 4 (US7157456B2)
JMC
2018
Diclofenac 2 4 (DE1793592)
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represent cases of 1-step conversion of drug analogues into
their queries). Third, the use of pseudo-retrosynthesis does
not decompose ligands into their actual precursors (e.g.,
the synthesis of Rivaroxaban contains a ring closure step
that cannot be reversed by fragmentation). Fourth, real
syntheses often involve protection chemistry, which is not
treated explicitly by reaction vectors.[10]
5 Conclusions
We have implemented a pseudo-retrosynthetic de novo
design tool referred to as RENATE that incorporates our
reaction-based structure generator. We have reported a
retrospective validation of the tool using a set of top
prescribed drugs to verify the assumptions on which it
relies and to determine an optimal configuration for real de
novo design. We have shown that the algorithm can explore
(i. e., direct the search towards the region of chemical space
occupied by the known drug) and also exploit (i. e.,
reproduce the reference drugs or at least generate very
similar candidates) chemical space effectively when suffi-
cient amounts of building blocks and reaction vectors are
provided. The algorithm has also been demonstrated to be
able to performs valid fragmentations, retrieve relevant
reagents, and combine them logically. The validation
presented here is based on the retrospective recreation of
known drugs with the scoring functions being based on
similarity to the target compound. While this strategy
presents a useful validation of the methods the real test of
the method would be the prospective design of previously
unknown compounds based on scoring functions such as
QSAR or docking. Such a prospective design will be
described in a future publication.
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